Limits...
A Macroporous Bioreactor Super Activated by the Recombinant Human Transforming Growth Factor-β(3).

Ripamonti U, Teare J, Ferretti C - Front Physiol (2012)

Bottom Line: Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone.On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs.The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

View Article: PubMed Central - PubMed

Affiliation: Bone Research Unit, Faculty of Health Sciences, School of Physiology, Medical Research Council/University of the Witwatersrand Johannesburg, South Africa.

ABSTRACT
Macroporous single phase hydroxyapatite (HA) and biphasic HA/β-tricalcium phosphate with 33% post-sinter hydroxyapatite (HA/β-TCP) were combined with 25 or 125 μg recombinant human transforming growth factor-β3 (hTGF-β(3)) to engineer a super activated bioreactor implanted in orthotopic calvarial and heterotopic rectus abdominis muscle sites and harvested on day 30 and 90. Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 μg hTGF-β(3), and 1:5 and 5:1 binary applications of hTGF-β(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-β(3). Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone. On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs. The induction of bone formation is controlled by the implanted ratio of the recombinant morphogens, i.e., the 1:5 hTGF-β(3):hOP-1 ratio by weight was greater than the inverse ratio. The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

No MeSH data available.


Related in: MedlinePlus

Distribution of newly formed bone, fibrovascular tissue and residual hydroxyapatite/calcium carbonate (HA/CC) material in heterotopic implants, 30 days after implantation with binary application of hTGF-β3: hOP-1 at 1:5 and 5:1 ratio by weight in coral-derived HA/CC implants with 5 and 13% conversion. Significant differences (p < 0.05), as detected by Bonferroni’s multiple comparison test, were noted for HACC 5% + hTGF-β3:OP-1 (1:5) and HACC 13% + hTGF-β3:OP-1 (1:5) compared to the inverse ratio (5:1).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3369251&req=5

Figure 15: Distribution of newly formed bone, fibrovascular tissue and residual hydroxyapatite/calcium carbonate (HA/CC) material in heterotopic implants, 30 days after implantation with binary application of hTGF-β3: hOP-1 at 1:5 and 5:1 ratio by weight in coral-derived HA/CC implants with 5 and 13% conversion. Significant differences (p < 0.05), as detected by Bonferroni’s multiple comparison test, were noted for HACC 5% + hTGF-β3:OP-1 (1:5) and HACC 13% + hTGF-β3:OP-1 (1:5) compared to the inverse ratio (5:1).

Mentions: The induction of bone by binary applications of hTGF-β3 and hOP-1 at 1:5 ratio by weight was greater than the quantity of bone in specimens pre-loaded with the inverse ratio of 5:1. 5% HA/CC, treated with the 1:5 ratio, yielded 38.30 ± 8.88% bone compared with 18.23 ± 8.41% at the 5:1 ratio (Figure 15). Statistically greater amounts of bone (p < 0.05), as detected by Bonferroni’s multiple comparison test, were generated in 13% HA/CC as compared to 5% HA/CC specimens with the hTGF-β3: hOP-1 at the 1:5 ratio than the inverse ratio (38.51 ± 3.60 vs. 7.70 ± 2.02%, respectively; Figure 15).


A Macroporous Bioreactor Super Activated by the Recombinant Human Transforming Growth Factor-β(3).

Ripamonti U, Teare J, Ferretti C - Front Physiol (2012)

Distribution of newly formed bone, fibrovascular tissue and residual hydroxyapatite/calcium carbonate (HA/CC) material in heterotopic implants, 30 days after implantation with binary application of hTGF-β3: hOP-1 at 1:5 and 5:1 ratio by weight in coral-derived HA/CC implants with 5 and 13% conversion. Significant differences (p < 0.05), as detected by Bonferroni’s multiple comparison test, were noted for HACC 5% + hTGF-β3:OP-1 (1:5) and HACC 13% + hTGF-β3:OP-1 (1:5) compared to the inverse ratio (5:1).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3369251&req=5

Figure 15: Distribution of newly formed bone, fibrovascular tissue and residual hydroxyapatite/calcium carbonate (HA/CC) material in heterotopic implants, 30 days after implantation with binary application of hTGF-β3: hOP-1 at 1:5 and 5:1 ratio by weight in coral-derived HA/CC implants with 5 and 13% conversion. Significant differences (p < 0.05), as detected by Bonferroni’s multiple comparison test, were noted for HACC 5% + hTGF-β3:OP-1 (1:5) and HACC 13% + hTGF-β3:OP-1 (1:5) compared to the inverse ratio (5:1).
Mentions: The induction of bone by binary applications of hTGF-β3 and hOP-1 at 1:5 ratio by weight was greater than the quantity of bone in specimens pre-loaded with the inverse ratio of 5:1. 5% HA/CC, treated with the 1:5 ratio, yielded 38.30 ± 8.88% bone compared with 18.23 ± 8.41% at the 5:1 ratio (Figure 15). Statistically greater amounts of bone (p < 0.05), as detected by Bonferroni’s multiple comparison test, were generated in 13% HA/CC as compared to 5% HA/CC specimens with the hTGF-β3: hOP-1 at the 1:5 ratio than the inverse ratio (38.51 ± 3.60 vs. 7.70 ± 2.02%, respectively; Figure 15).

Bottom Line: Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone.On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs.The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

View Article: PubMed Central - PubMed

Affiliation: Bone Research Unit, Faculty of Health Sciences, School of Physiology, Medical Research Council/University of the Witwatersrand Johannesburg, South Africa.

ABSTRACT
Macroporous single phase hydroxyapatite (HA) and biphasic HA/β-tricalcium phosphate with 33% post-sinter hydroxyapatite (HA/β-TCP) were combined with 25 or 125 μg recombinant human transforming growth factor-β3 (hTGF-β(3)) to engineer a super activated bioreactor implanted in orthotopic calvarial and heterotopic rectus abdominis muscle sites and harvested on day 30 and 90. Coral-derived calcium carbonate fully converted (100%) and partially converted to 5 and 13% hydroxyapatite/calcium carbonate (5 and 13% HA/CC) pre-loaded with 125 and 250 μg hTGF-β(3), and 1:5 and 5:1 binary applications of hTGF-β(3): hOP-1 by weight, were implanted in the rectus abdominis and harvested on day 20 and 30, respectively, to monitor spatial/temporal morphogenesis by high doses of hTGF-β(3). Bone formation was assessed on decalcified paraffin-embedded sections by measuring the fractional volume of newly formed bone. On day 30 and 90, single phase HA implants showed greater amounts of bone when compared to biphasic specimens; 5 and 13% HA/CC pre-loaded with 125 and 250 μg hTGF-β(3) showed substantial induction of bone formation; 250 μg hTGF-β(3) induced as yet unreported massive induction of bone formation as early as 20 days prominently outside the profile of the macroporous constructs. The induction of bone formation is controlled by the implanted ratio of the recombinant morphogens, i.e., the 1:5 hTGF-β(3):hOP-1 ratio by weight was greater than the inverse ratio. The unprecedented tissue induction by single doses of 250 μg hTGF-β(3) resulting in rapid bone morphogenesis of vast mineralized ossicles with multiple trabeculations surfaced by contiguous secreting osteoblasts is the novel molecular and morphological frontier for the induction of bone formation in clinical contexts.

No MeSH data available.


Related in: MedlinePlus